Comparison Study of Two Supraglottic Devices Used for Patients Under General Anesthesia

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2009 by Maisonneuve-Rosemont Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Maisonneuve-Rosemont Hospital
ClinicalTrials.gov Identifier:
NCT01001078
First received: October 21, 2009
Last updated: October 22, 2009
Last verified: October 2009
  Purpose

This study will compare two supraglottic airway devices currently on the market. Supraglottic airway devices are used during general anesthesia to provide a patent airway. They are inserted blindly into the mouth once the patient has lost consciousness and they cover the laryngeal inlet. The I-Gel and the Supreme LMA are the two devices to be compared. The I-Gel has no inflatable cuff, which makes it different from all other supraglottic airway devices currently in use. The Supreme shares some characteristics of the other LMA devices, but it is disposable. Our main goal will be to compare the airway leak pressure and the peak airway pressure of each devices. We will also measure the time needed for insertion, number of attempts needed to secure the airway and side effects related to the airway (cough, dysphagia, trauma, hoarseness of voice, sore throat).


Condition Intervention
Patent Airway
Device: Supraglottic airway device insertion

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Prospective Randomized Trial Comparing the Performance of Two Supraglottic Airway Management Devices: I-Gel and Supreme LMA

Further study details as provided by Maisonneuve-Rosemont Hospital:

Primary Outcome Measures:
  • Measure of the airway leak pressure [ Time Frame: After introduction of the supraglottic device ] [ Designated as safety issue: No ]
  • Measure of the peak airway pressure [ Time Frame: After introduction of the supraglottic device ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Time needed to secure the airway [ Time Frame: From opening of the mouth to thoracic expansion and presence of ETCO2 ] [ Designated as safety issue: No ]
  • Number of attempts to introduce the devices [ Time Frame: At the beginning of anesthesia ] [ Designated as safety issue: No ]
  • Adverse effects after anesthesia (cough, sore throat, dysphagia, trauma, dysphonia) [ Time Frame: At discharge from post anesthesia care unit and on the day following surgery ] [ Designated as safety issue: No ]
  • Airway manipulation [ Time Frame: During anesthesia ] [ Designated as safety issue: No ]

Estimated Enrollment: 100
Study Start Date: September 2009
Groups/Cohorts Assigned Interventions
I-Gel
Group in which the I-Gel will be used in the first and second attempts to secure the airway. If a third attempt is needed, the LMA Supreme will be used. If the third attempt fails, a standard endotracheal tube will be used.
Device: Supraglottic airway device insertion

In the I-Gel group, 2 attempts to secure the airway will be tried. If they both fail, there will be a crossover with a Supreme LMA. Peak and mean airway pressure will be measured once the device is fixed with tape to the patient. Leak pressure will be measured as well. It will be done while closing the Adjustable Pressure Limiting valve and putting the fresh gas flow at 3 L/min. We will be looking at the manometer to see either a plateau (that would be a leak equal to the fresh gas flow) or the maximum allowed pressure 40 cm H2O.

In the LMA Supreme group, the same interventions will be done as in the I-Gel group. The cuff of the LMA Supreme will be inflated with 25 mL of air and then by intervals of 5 mL until no leak is heard (max 45 mL). Leak pressure will also be measure at 45 mL. Once the leak test is done, the cuff will be deflated to initial volume necessary to avoid audible leaks.

LMA Supreme
Group in which the LMA Supreme will be used in the first and second attempts to secure the airway. If a third attempt is needed, the I-Gel will be used. If the third attempt fails, a standard endotracheal tube will be used.
Device: Supraglottic airway device insertion

In the I-Gel group, 2 attempts to secure the airway will be tried. If they both fail, there will be a crossover with a Supreme LMA. Peak and mean airway pressure will be measured once the device is fixed with tape to the patient. Leak pressure will be measured as well. It will be done while closing the Adjustable Pressure Limiting valve and putting the fresh gas flow at 3 L/min. We will be looking at the manometer to see either a plateau (that would be a leak equal to the fresh gas flow) or the maximum allowed pressure 40 cm H2O.

In the LMA Supreme group, the same interventions will be done as in the I-Gel group. The cuff of the LMA Supreme will be inflated with 25 mL of air and then by intervals of 5 mL until no leak is heard (max 45 mL). Leak pressure will also be measure at 45 mL. Once the leak test is done, the cuff will be deflated to initial volume necessary to avoid audible leaks.


  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Any subject planned to have general anesthesia for elective surgery

Criteria

Inclusion Criteria:

  • Weight more than 50 kg;
  • Body Mass Index less than 30;
  • ASA I to III.

Exclusion Criteria:

  • Symptomatic gastro oesophageal reflux disease (GERD);
  • Non fasted patients;
  • Nasogastric tube in place;
  • Intestinal obstruction;
  • ENT surgery in the past or deformation of the airway;
  • Known difficult airway (Cormack-Lehane grade 3-4);
  • Oral cavity opening less than 3 cm;
  • Pregnancy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01001078

Contacts
Contact: Nikola Joly, MD +1 514 252 3426 nikola.joly@umontreal.ca
Contact: Pierre Drolet, MD, FRCPC +1 514 252 3426 pierre.drolet@umontreal.ca

Locations
Canada, Quebec
Hôpital Maisonneuve-Rosemont Recruiting
Montréal, Quebec, Canada, H1T 2M4
Sponsors and Collaborators
Maisonneuve-Rosemont Hospital
Investigators
Principal Investigator: Pierre Drolet, MD, FRCPC Hôpital Maisonneuve-Rosemont, Université de Montréal
  More Information

No publications provided

Responsible Party: Pierre Drolet, Hôpital Maisonneuve-Rosemont
ClinicalTrials.gov Identifier: NCT01001078     History of Changes
Other Study ID Numbers: HMR-Anesth-Joly
Study First Received: October 21, 2009
Last Updated: October 22, 2009
Health Authority: Canada: Health Canada

Keywords provided by Maisonneuve-Rosemont Hospital:
supraglottic airway devices
I-Gel
Supreme Laryngeal mask airway
Airway leak pressure
peak airway pressure

ClinicalTrials.gov processed this record on October 20, 2014